Current Report Filing (8-k)
16 November 2021 - 09:17AM
Edgar (US Regulatory)
0001818382
false
0001818382
2021-11-15
2021-11-15
0001818382
us-gaap:CommonStockMember
2021-11-15
2021-11-15
0001818382
HUMA:RedeemableWarrantsEachWholeWarrantExercisableForOneOfCommonAtExercisePriceOf11.50Member
2021-11-15
2021-11-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported):
November 15, 2021
Humacyte, Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-39532
|
|
85-1763759
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification Number)
|
2525 East North Carolina Highway 54
Durham, NC
|
|
27713
|
(Address of principal executive offices)
|
|
(Zip code)
|
(919) 313-9633
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common
Stock, par value $0.0001 per share
|
|
HUMA
|
|
The Nasdaq Stock Market LLC
|
Redeemable
Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50
|
|
HUMAW
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
Item 8.01. Other Events
On
November 15, 2021, Humacyte, Inc. (the “Company”) issued a press release announcing data from a Phase 2 clinical trial of
patients receiving the human acellular vessel (HAV) produced using the Company’s cutting-edge, large-scale manufacturing
systems, known as “LUNA200,” for vascular access in hemodialysis. A copy of this press release is filed as Exhibit 99.1 to
this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
HUMACYTE, INC.
|
|
|
|
Date: November 15, 2021
|
By:
|
/s/ Dale A. Sander
|
|
|
Name:
|
Dale A. Sander
|
|
|
Title:
|
Chief Financial Officer, Chief Corporate Development Officer and Treasurer
|
Alpha Healthcare Acquisi... (NASDAQ:AHACU)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alpha Healthcare Acquisi... (NASDAQ:AHACU)
Historical Stock Chart
From Mar 2023 to Mar 2024
Real-Time news about Alpha Healthcare Acquisition Corporation (NASDAQ): 0 recent articles
More Humacyte, Inc. News Articles